阿立哌唑辅助氟伏沙明治疗难治性抑郁症的疗效分析

目的:探讨阿立哌唑辅助氟伏沙明治疗难治性抑郁症的临床效果及安全性。方法:将58例难治性抑郁症患者随机分为研究组和对照组,各29例。对照组给予氟伏沙明(250~300 mg/d)治疗,研究组给予氟伏沙明(250~300 mg/d)联合阿立哌唑(2.5~7.5 mg/d)治疗。治疗观察期均为8周。两组患者于基线及治疗后1、2、4、8周末采用24项汉密尔顿抑郁量表(HAMD-24)评定治疗效果,并采用副反应量表(TESS)评定治疗期间的不良反应。结果:研究组在1、2、4、8周末的抑郁症状评分间差异均有统计学意义(P均<0.05);8周末时两组有效率差异有统计学意义(P<0.05),而不良反应发生率差异无统计学意义(P>0.05)。结论:阿立哌唑辅助氟伏沙明治疗难治性抑郁症患者可持续、有效改善其抑郁症状,不良反应发生率与单用氟伏沙明治疗相当。

Efficacy of aripiprazole combined with fluvoxamine in the treatment of resistant depression

Objective ： To explore the efficacy and safety of aripiprazole combined with fluvoxamine in the treatment of resistant depression. Methods： 58 patients with resistant depression were ran- domly divided into study group and control group, 29 for each. Control group was treated with flu- voxamine（250-300 mg/d） while study group was treated with aripiprazole （2.5 -7.5 mg/d） combined with fluvoxamine （250 -300 mg/d）. Each group had a 8-week course of treatment. The efficacy were assessed and analyzed by 24-item Hamilton Depression Scale （HAMD-24） at base- line,1,2,4 and 8 weeks after treatment. The side effects were assessed by Treatment Emergent Symptom Scale（TESS） during the treatment. Results： The scores of depressive symptoms in study group were statistically different at 1,2, 4 and 8 weeks after treatment（P 〈 0.05）. The effective rates were statistically different in two groups（P 〈 0.05 ）, while the occurrence rates of side effects had no statistical difference （P 〉 0.05 ）. Conclusion： Aripiprazole combined with fluvoxamine can effectively improve the depressive symptoms in patients with resistant depression, the incidence rates of side effects was similar to single fluvoxamine therapy.